TORL BioTherapeutics

TORL BioTherapeutics is a clinical-stage biotechnology company focused on discovering and developing antibody-based immunotherapies for cancer. They are developing a pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) targeting specific antigens overexpressed in cancer cells. Their work is based on a strategic partnership with the Slamon Research Lab at UCLA.


Buy Funded Startups lists

Funding Round: Series B2

Funding Amount: $158M

Date: 10-Apr-2024

Investors: Deep Track Capital, RA Capital Management, Perceptive Advisors, Avidity Partners, Goldman Sachs Alternatives, UC Investments, Bristol Myers Squibb, Vertex Ventures HC, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Perceptive Xontogeny Venture Fund

Markets: Biotechnology, Oncology, Immunotherapy, Biopharma, Clinical Trials, Drug Discovery

HQ: Culver City, California, United States

Founded: 2018

Website: https://torlbio.com/

LinkedIn: https://www.linkedin.com/company/torl-biotherapeutics-llc

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/torl-biotherapeutics

Pitchbook: https://pitchbook.com/profiles/company/523096-21


Leave a Comment